KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of “Moderate Buy” by Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has received a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $27.2857.

Several equities analysts have commented on KALV shares. Citizens Jmp lowered their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 11th. Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. JMP Securities raised their price objective on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a research note on Friday, September 12th. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 4th. Finally, Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV opened at $15.23 on Monday. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $17.30. The business has a 50 day simple moving average of $13.19 and a two-hundred day simple moving average of $13.31. The stock has a market capitalization of $769.88 million, a PE ratio of -3.86 and a beta of -0.14.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million for the quarter, compared to analysts’ expectations of $6.03 million. On average, research analysts predict that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Paul K. Audhya sold 5,296 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $71,231.20. Following the sale, the insider directly owned 131,831 shares in the company, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 10,940 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $147,143.00. Following the sale, the chief executive officer directly owned 416,189 shares of the company’s stock, valued at $5,597,742.05. This represents a 2.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 31,329 shares of company stock valued at $437,371. Company insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its stake in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in KalVista Pharmaceuticals in the 3rd quarter worth about $55,000. Wolverine Asset Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the third quarter worth approximately $57,000. KLP Kapitalforvaltning AS bought a new stake in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $63,000. Finally, Virtus Investment Advisers LLC purchased a new stake in shares of KalVista Pharmaceuticals in the second quarter valued at approximately $81,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.